New study below [1].
OK, so you are wondering how tall can those NBL rats be? How much a year do they earn? NBL rats are 'Noble' rats. Sometimes an abbreviation doesn't save much space & takes longer to say.
MC Bosland has been messing about with rats for 40 years. There are studies by others going back as far as 30 years where Noble rats were given testosterone [T] & estradiol [E2] to induce prostatic hyperplasia, etc. What's new about this study?
"Androgens are thought to cause prostate cancer, but the underlying mechanisms are unclear. Data from animal studies suggest that for androgens to cause prostate cancer, they must be aromatized to estrogen and act in concert with estrogen metabolites. We tested the hypothesis that androgen-receptor and estrogen receptor-mediated effects of androgen and estrogen are necessary, as well as genotoxicity of estrogen metabolites. NBL rats were treated with androgenic and estrogenic compounds for 16-75 weeks through slow-release silastic implants or pellets."
"5α-Dihydrotestosterone, which cannot be converted to estradiol or testosterone, did not cause a significant prostate cancer incidence (4%)."
"Testosterone alone {which can be converted to estradiol} induced cancer in the prostate of 37% of rats."
"Addition of estradiol to 5α-dihydrotestosterone treatment did not markedly enhance prostate cancer incidence (14%)"
"adding estradiol to testosterone treatment ... induced a 100% tumor incidence."
"results strongly support the hypothesis"
Going back 15 years, the literature was suggestive to me that in estrogen dominance, E2 drives proliferation while T is necessary but merely permissive. With T:E2 balance, though, T resumes its growth regulatory role.
But nobody seems to care about E2, or the fact the the T:E2 ratio is much reduced in men by the time they are diagnosed.
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/308...
Horm Cancer. 2019 Mar 16. doi: 10.1007/s12672-019-00360-7. [Epub ahead of print]
Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats.
Ozten N1, Vega K2,3, Liehr J4, Huang X2,5, Horton L2, Cavalieri EL6, Rogan EG6, Bosland MC7,8.
Author information
Abstract
Androgens are thought to cause prostate cancer, but the underlying mechanisms are unclear. Data from animal studies suggest that for androgens to cause prostate cancer, they must be aromatized to estrogen and act in concert with estrogen metabolites. We tested the hypothesis that androgen-receptor and estrogen receptor-mediated effects of androgen and estrogen are necessary, as well as genotoxicity of estrogen metabolites. NBL rats were treated with androgenic and estrogenic compounds for 16-75 weeks through slow-release silastic implants or pellets. Testosterone alone induced cancer in the prostate of 37% of rats. 5α-Dihydrotestosterone, which cannot be converted to estradiol or testosterone, did not cause a significant prostate cancer incidence (4%). Addition of estradiol to 5α-dihydrotestosterone treatment did not markedly enhance prostate cancer incidence (14%), unlike adding estradiol to testosterone treatment which induced a 100% tumor incidence. Testosterone plus estradiol treatment induced a DNA adduct detectable by 32P-postlabeling, oxidative DNA damage (8-hydroxyguanosine), and lipid peroxidation at the site within the prostate where this treatment causes cancers, preceding later cancer formation. The non-estrogenic 4-hydroxy metabolite of estradiol, when combined with testosterone, induced prostatic dysplasia within 16 weeks and, after long-term treatment, a very low incidence of prostate cancer (21%). When an estrogen that cannot be hydroxylated (2-fluoroestradiol) was added to this combined treatment with testosterone and 4-hydroxyestradiol, dysplasia frequency after 16 weeks was doubled. These results strongly support the hypothesis, but additional definitive studies are needed which may identify new targets to interfere with these mechanisms that are clinically feasible in humans.
KEYWORDS:
Androgen; Estrogen; Hormonal carcinogenesis; Prostate cancer
PMID: 30877616 DOI: 10.1007/s12672-019-00360-7